Chronic intracranial neural dynamics forecast treatment response and therapeutic engagement during deep brain stimulation for OCD

TL;DR: A single number computed once a day from a DBS implant — how well yesterday's brain activity predicts today's — tracks whether an OCD patient is responding to stimulation, and it moves within the first two weeks of therapy, roughly six months before the symptoms do. Across 24 patients and ~120,000 hours of chronic intracranial recordings (the largest longitudinal sensing cohort in psychiatric DBS to date), the authors show this "neural predictability" biomarker separates responders from non-responders during chronic therapy (AUROC up to 0.95), forecasts eventual symptom improvement from the first 14 days of stimulation, and — most provocatively — that circadian structure in the signal before stimulation ever turns on predicts who will respond.

The problem: flying blind for six months

Deep brain stimulation for treatment-resistant OCD works — about 60% of patients in this cohort achieved clinical response (≥35% reduction on the Y-BOCS symptom scale). But it works slowly. Responders in this study took an average of 206 days to reach stable response. During that window, clinicians iterate through stimulation contacts, amplitudes, and pulse widths by trial and error, with feedback arriving only at clinic visits weeks or months apart. If a patient isn't improving at month four, is the therapy failing, or does it just need more time? Nobody knows, and that uncertainty is expensive — for programming, for patient morale, and for deciding when to try a different contact.

The tantalizing asymmetry is that the implant itself is recording continuously. Medtronic's Percept devices log local field potential (LFP) power from the stimulation site — here the ventral capsule/ventral striatum (VC/VS), a white-matter hub interconnecting prefrontal, striatal, and extended-amygdala circuits implicated in OCD. So you have neural data every 10 minutes and clinical ground truth every couple of months. The question is whether the dense stream carries information about the sparse one — and, better, about its future.

The signal is almost comically minimal

It's worth pausing on how little data this method uses, because it explains both why it's deployable and why it's surprising that it works. BrainSense Timeline mode gives you one number every 10 minutes: average LFP power in a single 5 Hz band (centered at 8.79 Hz here — call it 9 Hz), from a bipolar pair straddling the active stimulation contact. That's 144 samples a day. No raw waveform, no broadband spectrum, no spatial coverage. The entire ~120,000-hour dataset is, informationally, a set of very long univariate time series.

The authors' previous work (Provenza et al., Nat Med 2024, 12 patients) noticed something in these traces: during symptomatic periods, the 9 Hz power follows a smooth, stereotyped circadian arc, day after day. After successful DBS, the trace gets messier — punctuated by transient high-amplitude deflections that break the daily ritual. The disorder that is behaviorally defined by rigid repetition apparently has a neural signature that is temporally rigid too.

The biomarker: can yesterday predict today?

To quantify that rigidity prospectively, they use about the simplest model imaginable — a lag-1 linear autoregressive model:

where x_t is the z-scored 9 Hz power at 10-minute sample t, \phi_1 is the single learned coefficient, and \epsilon_t is the residual. Each day, the model is fit by least squares on the preceding two days and used to predict the third. Daily neural predictability is the coefficient of determination R^2 between predicted and observed activity. Since the fitted \phi_1 is just under 1, the prediction is essentially "same as ten minutes ago, slightly attenuated" — so R^2 is high when the signal glides smoothly (stereotyped circadian sweep) and low when it jumps around (transient deflections). It's a one-parameter measure of temporal stereotypy, computable causally, every day, on-device-adjacent hardware. They also report that fancier multi-lag AR models (up to 144 lags) buy nothing over the single-lag version.

Three results, at three stages of therapy

Stage 3 first (chronic tracking), because it's the replication. Responders showed a large, significant drop in daily R^2 from pre-DBS to stable response (p \approx 9\times10^{-19}, with effective-sample-size correction for autocorrelation); non-responders showed none (p = 0.424). Because baseline predictability varies a lot across people (mean 0.49, SD 0.15), the strongest feature is \Delta R^2 — change from each patient's own pre-DBS baseline. In leave-one-patient-out logistic regression classifying each day as response vs. non-response, daily R^2 gives AUROC 0.79, a 14-day moving average gives 0.83, and 14-day-averaged \Delta R^2 gives 0.950 (balanced accuracy 0.886, patient-weighted metrics similar). The effect is left-hemisphere specific — right-hemisphere data don't discriminate at all (p = 0.60) — which the authors connect to prior lateralization reports but which should also make you a bit uneasy (more below).

Stage 2 (early forecasting) is the headline. In all five patients with recordings spanning pre-DBS through response, the 7-day-averaged \Delta R^2 crossed the (held-out, per-fold) decision threshold within 14 days of DBS activation — versus ~7 months to clinical response. Group separation between eventual responders and non-responders was already significant by day 4. Responders spent 83.6% of the post-DBS period below threshold; non-responders 11.6%. Crucially, this isn't just binary: the average \Delta R^2 over the first two weeks correlated with each patient's eventual Y-BOCS reduction at last follow-up (r = -0.725, p = 7.6\times10^{-3}) — a dose-response-like relationship that's harder to get by luck than a group difference. And it isn't explained by stimulation settings: amplitude and pulse width at day 14 didn't differ between groups.

Stage 1 (pre-treatment forecasting) is the newest and most fragile claim. Even before stimulation, eventual responders and non-responders had different circadian organization of 9 Hz power: significantly different acrophase (time of daily peak; p = 0.021, circular statistics with permutation testing) and different time-of-day power in three of four 6-hour bins (strongest in late morning, p = 6.8\times10^{-3}). A leave-one-out LDA classifier on pre-DBS time-binned power classified eventual responder status correctly in 12 of 14 patients (AUROC 0.833, p = 0.0098 vs. shuffled labels). Effective DBS then dismantled this circadian architecture in responders — the 12-hour and 24-hour spectral components dropped significantly — while non-responders' rhythms stayed put.

Why this framing is interesting beyond OCD

Most DBS biomarkers are of the form "power in band X correlates with symptom Y right now" — a state readout. This one is different in two ways.

First, it measures temporal organization rather than amplitude. The claim, echoing dynamical-systems views of brain function, is that pathology here is a rigidity of dynamics — an attractor too deep — and that effective stimulation restores flexibility, widening the repertoire of accessible states. OCD is behaviorally the disorder of stereotyped loops; finding that its target-region physiology is literally more autocorrelated, and that therapy de-correlates it, is a satisfying mechanistic rhyme. The authors are careful to hypothesize rather than assert: the deflections that kill predictability may reflect re-engagement with motivationally salient events as patients exit avoidance-dominated behavior. That would make the biomarker partly behavioral in origin — brain and lifestyle rigidity are confounded in a signal recorded during everyday life, and the current data can't separate them.

Second, and more useful clinically, it appears to be a target-engagement marker rather than a symptom meter. Two within-patient episodes make this point: one patient relapsed for ~10 months years after responding, and another had a severe symptomatic worsening during the transition period — in both, predictability stayed low. The biomarker seems to report "stimulation is engaging the circuit," not "the patient feels fine today." That dissociation is exactly what you want for programming: an objective readout, available within days of a parameter change, that tells you whether you're in the right place — decoupled from the slow, noisy behavioral response. If validated, this is the piece that changes practice: try a contact, wait two weeks, read \Delta R^2, decide.

How much should you believe it?

This is a careful paper with real methodological hygiene — leave-one-patient-out everywhere, decision thresholds derived only from training folds, effective-sample-size corrections for autocorrelated daily data, patient-weighted metrics, permutation-based nulls, FDR correction. But the honest accounting is sobering on N:

• The forecasting claim (Fig. 4) rests on 5 responders vs. 6 non-responders — the patients with both pre-DBS and post-outcome recordings. "5/5 crossed the threshold within 14 days" is striking but is a coin that's only been flipped five times. The r = -0.725 correlation is over ~11 points.
• The pre-DBS circadian classifier is 14 patients, and the analysis is explicitly exploratory: time-bins were selected per-fold, but the whole family of circadian features (acrophase, PSD components, time-of-day bins) was explored on this same cohort. The p-values here (0.02–0.04 range, after correction) would not survive a much harsher multiplicity accounting.
• Half the cohort (12/24) overlaps with the discovery cohort from the 2024 paper where the 9 Hz band and predictability concept were identified. The new prospective AR(1) implementation and 12 new patients constitute genuine extension, but this is not a fully independent replication.
• Left-hemisphere-only discriminability has literature precedent but is also the kind of degree of freedom that inflates effective comparisons.
• Ground truth is soft: Y-BOCS every few weeks-to-months, carried forward between assessments, with transition periods excluded. The "day-level classification" AUROC of 0.95 is really classifying long blocks of days sharing one label — the patient-weighted numbers are the right ones to quote, and to the authors' credit they do.
• One narrow band, one region, one device. Whatever broadband physiology underlies the deflections is invisible here.

The authors flag most of this themselves and call for prospective, multi-center validation with denser behavioral sampling. The right prior: chronic tracking (Stage 3) is now well-supported; early forecasting (Stage 2) is promising and mechanistically coherent but needs ~5× the patients; pre-treatment prediction (Stage 1) is a hypothesis-generating result.

What to read, and what it connects to

If you read one section, read the early-forecasting results (Fig. 4) plus the discussion of the two dissociation cases (B001's transient worsening, B014's relapse) — together they carry both the clinical value proposition and the most interesting scientific claim (engagement marker, not symptom meter). The Methods on threshold derivation and effective-sample-size correction are worth skimming to calibrate trust in the statistics.

The broader significance: this is what invasive psychiatric BCI looks like when it grows up — not decoding thoughts, but extracting one robust, interpretable, prospectively computable scalar from a commercial implant's telemetry and attaching it to concrete clinical decisions (patient selection, contact programming, relapse surveillance). The AR(1)-on-a-single-band simplicity is a feature: it runs on data every Percept patient worldwide is already generating, and the team ships an open-source app for exactly that. If the two-week forecast survives a prospective trial, the same "temporal predictability as circuit rigidity" lens is an obvious thing to try in depression DBS, adaptive stimulation, and even non-invasive longitudinal recordings.